Cocrystal Pharma Inc. (COCP) and Scholar Rock Holding Corporation (NASDAQ:SRRK) Comparison side by side

This is a contrast between Cocrystal Pharma Inc. (NASDAQ:COCP) and Scholar Rock Holding Corporation (NASDAQ:SRRK) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cocrystal Pharma Inc. N/A 0.00 N/A 0.04 93.68
Scholar Rock Holding Corporation N/A 0.00 42.82M -1.74 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Cocrystal Pharma Inc. 0.00% 0.4% 0.4%
Scholar Rock Holding Corporation 0.00% 0% 0%

Liquidity

The Current Ratio and Quick Ratio of Cocrystal Pharma Inc. are 4.4 and 4.4 respectively. Its competitor Scholar Rock Holding Corporation’s Current Ratio is 18.4 and its Quick Ratio is 18.4. Scholar Rock Holding Corporation can pay off short and long-term obligations better than Cocrystal Pharma Inc.

Institutional & Insider Ownership

Roughly 8.2% of Cocrystal Pharma Inc. shares are owned by institutional investors while 51% of Scholar Rock Holding Corporation are owned by institutional investors. Insiders owned roughly 67.48% of Cocrystal Pharma Inc.’s shares. Competitively, Scholar Rock Holding Corporation has 19.6% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cocrystal Pharma Inc. 1.71% 118.4% 11.25% 24.04% -47.49% -40.67%
Scholar Rock Holding Corporation 5.3% 4.74% 1.02% 48.18% 0% 65.48%

For the past year Cocrystal Pharma Inc. has -40.67% weaker performance while Scholar Rock Holding Corporation has 65.48% stronger performance.

Summary

Cocrystal Pharma Inc. beats Scholar Rock Holding Corporation on 5 of the 7 factors.

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company was founded in 2012 and is based in Cambridge, Massachusetts.